GOURI in Daegu: seven things to check before you choose a clinic
If you searched for the clinic that “does GOURI best” in Daegu, what is actually useful is not an answer but a way to judge. No public metric compares operator skill. What anyone can compare is what a clinic checks during the consultation.
The short answer
Before GOURI (liquid-form polycaprolactone), seven things matter more than reputation — ①how your skin structure was assessed ②whether the problem is thickness, volume or descent ③whether there is any published basis for the dose used in that area ④whether you were told the material cannot be dissolved ⑤how it differs from other collagen stimulators, in data ⑥whether the session interval comes from the manufacturer or from market habit ⑦whether there is a defined procedure if something goes wrong. Each one can be settled with a single question in the consultation room.
Why a checklist instead of a ranking
There is no public data comparing injector skill. Case volume, review counts and search visibility have never been shown to track outcomes. We have no basis to claim we are better, either.
What can be compared is what gets measured in the consultation, which numbers are stated out loud, and what the clinic refuses to do. The seven items below are the order we actually work through, and every one of them is something you can verify anywhere.
There are no prices here. Miso Clinic does not discuss treatment costs in columns or on the website. With a material that cannot be reversed, putting price first in the decision costs you the chance to check the other six items.
1. Skin structure assessment — what was the judgment based on?
A face does not age for one reason. Dermal thinning and texture, fat atrophy and migration, soft-tissue descent, skeletal change, pigment and vessels are all mixed together, and GOURI aims at the first of those only.
So the first thing to separate is not a product but what has been lost. If a hollow cheek is fat atrophy, no booster will fill it; if it is descent, the conversation belongs to lifting. A consultation that starts from a product name has the order reversed.
The question to ask
“In my case, is this thinner skin, lost volume, or descent?” Watch for an answer broken down by area. Most people have all three, and in that case the honest answer states the proportions.
At this step GOURI often drops out of consideration in our clinic. That is a normal outcome, not a failed consultation.
2. Skin thickness and degree of descent — is thinner better?
Liquid-form PCL is a particle-free aqueous solution that spreads thinly in the dermis, which is why it is often described as suited to thin, dry skin. The direction is plausible. One distinction has to be kept.
No human study has compared outcomes by skin thickness. The published human data for GOURI totals 33 subjects (a 30-patient pilot plus three case reports) with a longest follow-up of six months. That is not enough for subgroup analysis. “Suited to thin skin” is therefore inferred from the formulation, not measured.
Descent is clearer. When sagging is the main complaint, there is no data showing that a dermal booster lifts anything. Descent belongs to energy devices, threads or surgery; boosters sit on top of that as skin-quality work.
| State | Where GOURI sits |
|---|---|
| Thin, dry, coarsening texture | A candidate — though “the dermis gets thicker” has not been measured in humans |
| Volume loss is the main issue | Not a candidate — a liquid formulation is not a filler |
| Descent is the main issue | Not a candidate — wrong layer |
| Irreversible material already in that area | We hold — see item 4 |
| Pigment or vascular concerns | Not a candidate — brown and red are different problems |
The longer version is in GOURI in Daegu: which skin types is it actually for.
3. Dose per area — is there a standard, or not?
Our answer here is not a comfortable one. We could not find primary data defining a dose per facial area.
Published protocols go only as far as stating that the product was distributed across multiple facial points (one case series used a 31G needle and ten points). No study compares volumes by area. So the volume used is the injector's judgment — which is not wrong in itself, but if someone calls it “the standard dose”, the source is worth asking for.
The manufacturer's own position on where is worth quoting as it stands. The official FAQ recommends use on the face only and says clinical data for hands and neck is “being collected”. A contributed article from the same company, meanwhile, lists neck, décolletage, periorbital area, elbows and knees. The two documents do not say the same thing.
The question. “Is there data for this area?” If neck, dorsal hands or the under-eye area has been suggested to you, this is the most useful sentence you can say. “There is no data, but it has worked in my hands” is also an honest answer — it simply leaves the judgment with you.
4. What PCL being irreversible means
This is the important one. Polycaprolactone is not hyaluronic acid, so hyaluronidase does not dissolve it. If you dislike the result there is no reversal agent; what remains is time, and physical removal.
We therefore say this sentence before describing the procedure itself. Then we check whether irreversible material — PCL, PLLA, CaHA — is already present in the same area. Layering another non-reversible material on top of records nobody has makes it impossible to identify a cause later.
The composition figures disagree with each other
The manufacturer's consumer page states PCL 21%; the patent example states 25% by weight of copolymer in aqueous solution. We have not been able to retrieve the Korean marketing-authorisation text, because automated queries to the MFDS database are blocked. What this discrepancy means clinically has not been established either — but it is better to know that the sources disagree.
The mechanism, and how far it has been confirmed, is in how GOURI is said to build collagen.
5. How it differs from other collagen stimulators
“Collagen booster” is not an ingredient; it is an umbrella term. Products sold under it differ enormously in how much human data stands behind them.
| Product (class) | Human data | Reversible? |
|---|---|---|
| GOURI (liquid PCL) | 33 subjects in total, six months at most | Not dissolvable |
| Rejuran (PN) | Korean phase 3, 70 analysed (95.7% vs 94.3% improvement) | N/A (degrades) |
| Rituo (hADM) | One trial, 20 subjects, 20 weeks | Not dissolvable |
| Juvelook (PDLLA) | Subject count not stated, no control arm, six months | Not dissolvable |
| Sculptra (PLLA) | FDA registration trial, 233 subjects, 25 months — rated “of low quality” in a 2024 systematic review | Not dissolvable |
Thicker data does not mean a better treatment; these products aim at different things. But if you are told one product is simply the best, how many subjects and which study is a fair question. The full comparison is in GOURI vs Rejuran vs Rituo vs Juvelook vs Sculptra.
The most common misattribution. Human biopsy data from 13 subjects and post-market data from 323,726 syringes belong to microsphere PCL (Ellansé), a different formulation. No study has compared the two formulations head to head in humans, so those numbers are not GOURI's.
6. Session interval — three different numbers
This is the easiest item to check, because the answers disagree.
| Source | What it says |
|---|---|
| Manufacturer FAQ | One session recommended, optionally 1–2 more at 4–6 week intervals |
| Common market claim | Three sessions, 3–4 weeks apart — we could not find a primary source |
| Published studies | Two sessions in the 30-patient pilot; one in the case reports |
So “three sessions” is not the manufacturer's default. There may be reasons to recommend three, but they do not come from the manufacturer's documentation. Asking “why this number of sessions?” is the fastest way to see what a clinic treats as evidence.
7. Adverse events and aftercare — is there a defined path?
We found no reports of nodules with GOURI. That sentence means not “it is rare” but “an incidence cannot be calculated” — the denominator is 33. No number is not the same as zero per cent.
Aftercare therefore has to lean on data from injectables in general: delayed nodules in 0.33% of 2,139 hyaluronic acid filler patients; 1 event (0.8%, at day 122) in 131 patients given a dermal-injection product; zero nodules across 1,111 microsphere-PCL treatments followed for three years. Delayed reactions peak three to four months after injection, and anything palpable within the first two weeks is usually a non-inflammatory lump.
What to ask
- “If something happens, who sees me, and when?” With irreversible material, having a defined first-response route matters more than reassurance.
- “At what point should I call about swelling or a lump?” Two weeks is the line that separates two different things.
- “You know hyaluronidase will not fix this?” If that answer is vague, the rest will be too.
Do not wait if you have: swelling with redness, warmth and tenderness; pain that worsens on one side only; mottled or darkening skin; or a firm area that appears more than two weeks after treatment. Timing decides what these mean.
Lumpiness is covered in why lumps appear after GOURI, and nodules in general in if you can feel a nodule after treatment.
How Miso Clinic decides whether to treat
The same seven items, stated as our own criteria.
- We separate what has been lost first — skin quality, volume, descent — area by area, and we say plainly that GOURI addresses one of them.
- We turn the goal into a sentence. “Look generally better” cannot be assessed afterwards.
- We state that it is irreversible before describing the treatment.
- We map what is already in each area. If the record is unclear, we advise waiting.
- We give the limits of the evidence as numbers: 33 subjects, six months, no human biopsy, six weeks in animals. Deciding against treatment after seeing that table is a normal outcome.
- We quote the manufacturer's interval first: one session, optionally 1–2 more at 4–6 weeks.
- Where there is no data for an area, we say so. Off-face areas are “being collected” per the manufacturer's FAQ.
And what we do not do: we do not present testimonials or before-and-after photographs as evidence of effect, we do not use phrases like “no side effects” or “the best”, we do not ask for a same-day decision, and we do not disparage other clinics' work.
Our consultation sequence is set out in if you are having a GOURI consultation in Daegu.
Summary
Established
- Published human data for GOURI: 33 subjects, six months maximum
- Manufacturer FAQ: one session + optional 1–2 at 4–6 weeks, face only
- Polycaprolactone is not dissolved by hyaluronidase
- In a rat photoaging model (40 animals), dermal thickness and type I collagen rose significantly at six weeks
Not established
- Human histology for liquid-form PCL — we found none
- Dose per area; any study comparing session numbers or intervals
- Whether outcomes differ by skin thickness or type
- The Korean authorisation text (database queries blocked) — the composition discrepancy stands
- Nodule incidence — no reports found, but 33 subjects is not a denominator
Frequently asked questions
Which clinic in Daegu is best at GOURI?
That cannot be answered from data, because no public metric compares operator skill. What can be answered is how to judge: is the material reversible, how many human subjects support it, does the session interval come from the manufacturer, is there data for that area, and is there a defined path if something goes wrong. The seven items in this column are that method.
How many GOURI sessions do I need?
The manufacturer's FAQ recommends one session, optionally 1-2 more at 4-6 week intervals. The widely repeated 'three sessions, 3-4 weeks apart' has no primary source we could find. Published studies used two sessions in the 30-patient pilot and one in the case reports.
I was told GOURI suits thin skin.
That is inferred from the formulation rather than measured. The published human data totals 33 subjects, which is far too few for analysis by skin type. The direction may well be right; the point is to hear inference and measurement as different things.
Can the result be reversed if I dislike it?
There is no reversal agent. Polycaprolactone is not hyaluronic acid, so hyaluronidase does not dissolve it. What remains is time, and physical removal if something palpable persists. This is why we state it before describing the procedure.
Can it be used on the neck or the backs of the hands?
The manufacturer's official FAQ recommends the face only and says data for hands and neck is being collected. A contributed article from the same company lists neck, decolletage and the periorbital area, so the two documents disagree. If an off-face area is suggested to you, ask whether there is data for it.
Is there a standard dose per area?
We could not find primary data defining one. Published protocols only state that the product was distributed across multiple facial points. The volume is therefore the injector's judgment, and if it is described as a standard dose the source is worth asking for.
How often do nodules occur?
No reports were found for GOURI, but with a denominator of 33 that means an incidence cannot be calculated rather than that nodules are rare. For reference: delayed nodules in 0.33% of 2,139 hyaluronic acid filler patients, and 1 event (0.8%, day 122) among 131 patients given a dermal-injection product.
Can I come for a consultation without treatment?
Yes. In our clinic GOURI frequently drops out at steps 1-2, most often when volume loss or descent turns out to be the main issue. Deciding against treatment is a normal result of a consultation.
Read next
Product page
The product itself is set out here. GOURI: liquid polycaprolactone as a collagen stimulator
Who wrote this
Written and reviewed by Lee Chi-Hak, MD, medical director of Miso Clinic in Daegu, South Korea. Every study cited above is given together with its design, its size and the limitations the authors themselves recorded, and where we could not find data, we have said that we could not find any.
| Medical director | Lee Chi-Hak, MD |
|---|---|
| Address | 4F Bombom Building, 125 Dongdeok-ro, Jung-gu, Daegu, South Korea · Exit 1, Kyungpook National University Hospital Station |
| Phone | +82-53-428-2700 |
| Hours | Weekdays 11:00–19:00 (lunch 13:00–14:00) / Saturday 10:00–16:00 (no lunch break) / Closed Sundays and public holidays |
| Columns | All clinical columns |
| Reference library | All booster and device references |
References
- GOURI manufacturer's official FAQ — sessions (“one session recommended, optionally 1–2 follow-up sessions at 4–6 week intervals”) and site (“we recommend to use GOURI on the face only. We are collecting clinical data about other indications, such as hand, neck injections”). A contributed article from the same company lists neck, décolletage, periorbital area, elbows and knees — the two documents disagree.
- Ponzo M et al., PRS Global Open 2025;13(11), PMID 41210393 — 30-patient pilot of liquid-form PCL, six months. With a 2-case report (three months, ten facial points, 31G needle) and a single case report, total human data is 33 subjects.
- Rat photoaging model — 40 animals; dermal thickness (p < 0.001) and type I collagen (p = 0.003) significantly increased at six weeks; injected bolus dispersed within six hours, no granuloma.
- Composition figures — manufacturer consumer page states PCL 21%; the patent example states 25% by weight of copolymer in aqueous solution. The Korean marketing-authorisation text could not be retrieved (automated MFDS database queries are blocked).
- Human data by class — Rejuran (PN) Korean phase 3, 72 enrolled / 70 analysed, 95.7% vs 94.3% (J Korean Med Sci 2014;29(Suppl 3):S201–S209); Rituo (hADM) 20 subjects, 20 weeks (Int J Mol Sci 2026;27(5):2193, NCT07155278); Sculptra (PLLA) FDA registration trial, 233 subjects, 25 months, with the “of low quality” assessment from Signori R et al., Polymers (Basel) 2024;16(18):2564, PMID 39339028.
- Nodule reference figures — 0.33% of 2,139 hyaluronic acid filler patients; 1 event (0.8%, day 122) among 131 patients (Niforos F et al., Clin Cosmet Investig Dermatol 2019); zero across 1,111 microsphere-PCL treatments in 780 patients over three years (Lin SL, Christen MO, J Cosmet Dermatol 2020;19(8):1907). Timing definitions and the three-to-four-month peak: Convery C et al., J Clin Aesthet Dermatol 2021;14(7):E59; Alizadeh N et al., Dermatology and Therapy 2024.
- Korean Medical Service Act, article 56 — restricts presenting testimonials as evidence of effect, superlative or guarantee language, and patient inducement.
Everything in this column is general information and does not replace medical diagnosis or treatment. Effects and side effects vary with individual skin condition, age and underlying illness, and the same result is not guaranteed for everyone. Any decision to proceed should be made in an in-person consultation with a physician.
← Clinical columns · Reference library · Miso Clinic home
한국어 · English